Devin Incerti, PhD
Dr. Incerti specializes in simulation modeling, health econometrics, and cost-effectiveness analysis, and is the author of a number of open-source software packages for health-economic simulation modeling and value assessment. At PHE, he has worked across a number of disease areas including oncology, HIV/AIDS, pediatric disorders, organ transplantation, genetics, and rheumatoid arthritis. In addition to his role at PHE, he is the Lead Economist for the Open Source Value Project (OSVP) at the Innovation and Value Initiative (IVI).
PhD, Public Policy, Princeton University
BA, Mathematics-Economics and Political Science, University of California, San Diego
- Frasco MA, et al. Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a. J Med Econ. 2017.
- Jansen JP, et al. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017.
- Shahabi A, et al. Assessing variation in the cost of palivizumab for respiratory syncytial virus prevention in preterm infants. Pharmacoeconomics. 2017.
- Stevens W, et al. Short-term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol. 2017.